Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0213


Solid cancer: Evaluating potential efficacy of epigenetic drugs.

Chee-Seng Ku, MD, PhD

Affiliation: Chee-Seng Ku, Cancer Science Institute of Singapore, National University of Singapore, Singapore.


Current generation of targeted cancer drugs in the treatment of solid cancers, with the exceptions of trastuzumab and vemurafenib , resistance and disease progression limit the effectiveness of most signal transduction inhibitors available. Epigenomic drugs and microRNAs-based agents represent one of promising categories in clinical development to increase tumor cells sensitivity to combined therapeutics. Here, I discuss latest data and perspectives in overcoming current therapy resistance by treating solid tumors.

(Citation: Gastric & Breast Cancer 2012; 11(2): 102-107)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 23 April 2012